The influence of 1 alpha-hydroxycholecalciferol on left ventricular function in end-stage renal failure.
This study was designed to assess the influence of 1 alpha-hydroxycholecalciferol on left ventricular function in end-stage renal failure. Twelve patients, all of whom were on regular haemodialysis, were investigated. M-mode echocardiography and systolic time intervals were used to derive indices of left ventricular function. Measurements were performed before and six weeks after treatment with one microgram daily of 1 alpha-hydroxycholecalciferol. Fractional fibre shortening increased from 34.6 to 37.6% (p less than 0.025) and mean velocity of fibre shortening increased from 1.21 to 1.32 circ/sec (p less than 0.01). These changes were associated with a fall in the mean plasma parathyroid hormone concentration from 1883 to 1123ng/L (p less than 0.0025) and a rise in magnesium concentration from 0.89 to 1.06 mmol/L (p less than 0.0025); plasma calcium increased from 2.59 to 2.70mmol/L but this change was not significant. Our results indicate that 1 alpha-hydroxycholecalciferol improves left ventricular function in end-stage renal failure by influencing both the turnover or secretion of parathyroid hormone and the metabolism of calcium and magnesium ions.
D000328:Adult; D002112:Calcifediol; D002302:Cardiac Output / Q000187:drug effects*; D002306:Cardiac Volume; D009202:Cardiomyopathies / Q000209:etiology; D006352:Heart Ventricles / Q000503:physiopathology; D006801:Humans; D006887:Hydroxycholecalciferols / Q000097:blood / Q000494:pharmacology*; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000503:physiopathology*; D008274:Magnesium / Q000097:blood; D008875:Middle Aged; D009200:Myocardial Contraction; D010281:Parathyroid Hormone / Q000097:blood; D013318:Stroke Volume / Q000187:drug effects*
D006887:Hydroxycholecalciferols; D010281:Parathyroid Hormone; D008274:Magnesium; D002112:Calcifediol; C008088:alfacalcidol